Big Pharma Bags Its Biotech Prey

The patent cliff is taking its toll on big pharma, but that doesn't mean these companies are going to stand still and wither on the vine. In fact, three smart pharmaceuticals have snapped up hot biotechs with promising drug candidates to add to their portfolios. Watch and find out which companies bagged their prey and if the price they paid makes sense.

The beauty of big pharma is that they pay solid dividends while they develop new drugs. The Motley Fool has compiled a special free report outlining our nine top dependable dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your complimentary copy today at no cost! Just click here to discover the winners we've picked.

The article Big Pharma Bags Its Biotech Prey originally appeared on Fool.com.

Dave Williamson has no positions in the stocks mentioned above. The Motley Fool owns shares of AstraZeneca and GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.